TrialNeuro-oncology2025

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.

Jason Fangusaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.